Browse 45 distinct additional sources across all ten sprays. This shelf includes exact-ingredient experiments, mechanism reviews and delivery research. It is separate from the checked canine and clinical records above: a paper’s relationship to an ingredient is not a trial of the finished spray.
mechanism review
Oxytocin as an Indicator of Psychological and Social Well-Being in Domesticated Animals: A Critical Review
Rault JL, van den Munkhof M, Buisman-Pijlman FTA. Oxytocin as an Indicator of Psychological and Social Well-Being in Domesticated Animals: A Critical Review. Frontiers in Psychology. 2017;8:1521. doi:10.3389/fpsyg.2017.01521.
Species and research route: Review of domesticated-animal literature, including dogs; discusses endogenous oxytocin sampling and experimental delivery across studies rather than one standardized route.
What researchers found: The review reports that oxytocin research in domesticated animals is often conducted in socially relevant settings, with limited non-social controls and inconsistent control of emotional valence or arousal. It concludes that oxytocin actions are shaped by environmental and social context, evidence linking oxytocin directly to psychological states is limited, and it is premature to treat oxytocin as a validated welfare indicator because findings are few, discrepant, and methodologically non-standardized.
Relevance and study scope
This gives necessary context for reading the existing canine intranasal oxytocin studies: a change in social behavior under a particular test does not automatically mean generalized calm, and oxytocin biology should not be interpreted independently of the social setting and outcome measure.
This is a critical narrative review rather than a trial of Calm Companion. It does not test Selank, Semax, the three-ingredient combination, food exposure, or a finished spray, and its conclusions do not establish efficacy or safety in an individual dog.
exact ingredient study
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. doi:10.3389/fphar.2016.00031.
Species and research route: 30 male Wistar rats; single intranasal Selank at 300 micrograms/kg; frontal-cortex gene expression measured at 1 and 3 hours.
What researchers found: The investigators measured 84 neurotransmission-related genes and found significant mRNA changes in 45 genes at 1 hour and 22 genes at 3 hours after Selank or GABA exposure. Selank and GABA changes were positively correlated at 1 hour, but the patterns were not identical; the authors interpreted the results as consistent with a possible allosteric influence on GABAergic signaling, alongside effects involving other neurotransmitter systems. The paper itself states that further work is needed to define the mechanism across models.
Relevance and study scope
This adds molecular context for why Selank is studied in relation to inhibitory neurotransmission and stress-related behavior, without treating a rat gene-expression experiment as proof of a calming outcome in dogs.
The study used rats, not dogs, and measured short-term cortical mRNA changes rather than behavior, clinical anxiety, or welfare. The frontal-cortex samples were pooled by group and time point, the route was intranasal rather than food-based, and the experiment did not test oxytocin, Semax, the combined formula, or a finished spray.
exact ingredient study
The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228.
Species and research route: Adult male Wistar rats with permanent middle-cerebral-artery occlusion; repeated intraperitoneal Semax at 100 micrograms/kg at 15 minutes, 1, 4, and 8 hours; ischemic cortex transcriptomes assessed at 3 and 24 hours.
What researchers found: In this focal-ischemia model, Semax altered expression of 96 genes at 3 hours and 68 genes at 24 hours using the study's stated cutoff. More than half of the altered genes at the reported immune-response time point were related to immune processes, including immunoglobulin and chemokine genes; vascular-related genes also changed, including genes associated with endothelial development, cell migration, hematopoiesis, and vasculogenesis. The authors describe these as possible contributors to neuroprotection in ischemia, while noting that many altered genes have uncertain functional significance and that the mechanism remains complex.
Relevance and study scope
This paper shows that Semax research includes broad immune and vascular gene responses in a defined brain-injury model, which helps distinguish molecular and disease-model findings from claims about ordinary canine calm or social behavior.
This is an acute rat ischemia experiment using repeated intraperitoneal injections, not a dog study and not a stress or social-behavior study. Gene-expression changes do not establish a beneficial behavioral outcome, oral or food-route absorption, finished-spray stability, safety, or an effect of Semax combined with Selank and oxytocin.
mechanism review
Delta-sleep-inducing peptide (DSIP): an update
Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. doi:10.1016/0196-9781(86)90148-8. PMID:3550726.
Species and research route: Cross-species literature review covering animal and human studies; routes varied across the reviewed literature and were not a single DSIP administration experiment.
What researchers found: This review described additional reports of sleep-related and extra-sleep effects, distribution and immunochemical findings, and proposed links to adrenergic transmission. It stated that DSIP’s physiological functions and a possible adrenergic mechanism still required establishment rather than presenting a settled mechanism.
Relevance and study scope
It is useful broader reading because it places the older sleep claims, tissue-distribution observations, and mechanistic hypotheses in historical context while making clear that the biology was unresolved. That caution helps prevent an older animal or human result from being treated as proof of a predictable canine response.
This is a 1986 narrative review rather than a new controlled canine study, and its conclusions reflect the literature available at that time. It does not test oral or food delivery, the finished spray, or an owner-facing sleep outcome in dogs.
exact ingredient study
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. doi:10.1159/000118919. PMID:1299794.
Species and research route: 16 adults with chronic insomnia; double-blind matched-pairs parallel groups; intravenous DSIP at 25 nmol/kg on three afternoons, compared with glucose placebo.
What researchers found: Polysomnography showed higher sleep efficiency and shorter sleep latency with DSIP than placebo, and one subjective tiredness measure decreased within the DSIP group. The authors judged the statistically significant effects weak, noted that part of the difference could reflect an incidental placebo-group change, found no change in other measures including subjective sleep quality, and concluded that short-term DSIP was unlikely to provide major therapeutic benefit for chronic insomnia.
Relevance and study scope
This is direct human DSIP evidence and is valuable chiefly because it includes a controlled comparison and a restrained conclusion rather than a simple positive claim. It shows that even intravenous exposure produced limited and mixed findings, which is important context when considering extrapolation to a dog-food route.
The sample was very small, the participants were humans with chronic insomnia, and the route was intravenous rather than oral or food-applied. It did not study dogs, a metered spray, palatability, product stability, or routine evening use.
exact ingredient study
Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor
Graf MV, Schoenenberger GA. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. Journal of Neurochemistry. 1987;48(4):1252-1257. doi:10.1111/j.1471-4159.1987.tb05654.x. PMID:3029331.
Species and research route: In vitro rat pineal preparation; DSIP at 20-300 nM and phosphorylated DSIP analogue tested with norepinephrine, prazosin, and propranolol.
What researchers found: DSIP at 20-300 nM significantly enhanced norepinephrine-induced pineal N-acetyltransferase activity in the rat preparation, and a phosphorylated analogue showed a similar effect. Prazosin eliminated the enhancement, while propranolol reduced norepinephrine stimulation that remained increased by the peptide; the authors therefore proposed modulation involving alpha-1 adrenergic signaling.
Relevance and study scope
This gives a concrete laboratory mechanism behind one historical DSIP hypothesis: interaction with adrenergic signaling in a pineal enzyme system. It helps explain what researchers mean by a proposed mechanism without turning a cell-free or tissue preparation into evidence of sleep improvement in a dog.
The work used rat pineal tissue outside the animal and included a phosphorylated DSIP analogue, so it does not establish the same pathway in dogs or intact animals. It did not measure sleep, behavior, oral absorption, food-matrix exposure, or finished-spray performance.
delivery research
Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain
Zlokovic BV, Susic VT, Davson H, Begley DJ, Jankov RM, Mitrovic DM, Lipovac MN. Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. Peptides. 1989;10(2):249-254. doi:10.1016/0196-9781(89)90026-0. PMID:2547200.
Species and research route: Vascularly perfused in situ guinea-pig forebrain; luminal exposure to radiolabeled DSIP, with unlabelled DSIP, L-tryptophan, and vasopressin as competitors or comparators.
What researchers found: Radiolabeled DSIP entered perfused guinea-pig forebrain regions with measurable transfer constants. Excess unlabelled DSIP inhibited uptake toward mannitol-like values, and the data were interpreted as evidence for a high-affinity saturable transport process with binding at brain capillary membranes; L-tryptophan also inhibited transfer.
Relevance and study scope
This is useful delivery biology because it addresses a specific question behind CNS peptide research: whether DSIP movement at a blood-brain interface may involve a saturable process rather than simple unrestricted diffusion. It can help an owner understand why systemic exposure, transport, and brain availability are separate questions.
The experiment used an isolated perfused guinea-pig brain, not a living dog receiving DSIP by mouth or in food. It does not establish intestinal absorption, intact-peptide delivery, a dose for dogs, or a sleep or safety outcome for the finished spray.
exact ingredient study
Some pharmacological effects of delta-sleep-inducing peptide (DSIP)
Scherschlicht R, Aeppli L, Polc P, Haefely W. Some pharmacological effects of delta-sleep-inducing peptide (DSIP). European Neurology. 1984;23(5):346-352. doi:10.1159/000115712. PMID:6548967.
Species and research route: Rabbits and cats under normal or disturbed-sleep conditions, plus morphine-dependent mice; intravenous and subcutaneous synthetic DSIP injections.
What researchers found: In rabbits, intravenous 25 micrograms/kg and subcutaneous 1 mg/kg DSIP increased spindle-dominated light non-REM sleep and prevented stress-associated hyposomnia. In cats, the tested doses preferentially increased REM sleep and abolished morphine’s sleep-suppressant effect; in morphine-dependent mice, selected doses reduced naloxone-induced withdrawal jumping. The investigators reported indications of bell-shaped dose-response relationships in most settings.
Relevance and study scope
This primary study shows that DSIP findings varied by species, sleep state, endpoint, and dose, rather than producing one uniform sleep effect. That variability is directly relevant when interpreting the ingredient’s historical pharmacology without projecting it onto dogs or a food-bowl spray.
These were injected-animal experiments involving rabbits, cats, and mice, including drug-withdrawal models; none involved dogs, oral or food delivery, or the finished product. The dose-response observations and sleep-stage results cannot establish routine canine outcomes or safety.
mechanism review
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022.
Species and research route: Review of mainly rodent and other laboratory studies; included gastrointestinal injury models and varied experimental administration routes rather than a canine food route.
What researchers found: The review describes BPC-157 as the 15-amino-acid sequence GEPPPGKPADDAGLV and summarizes reported effects in experimental gastrointestinal lesions, intestinal anastomoses, fistulas, and tissue injury. It discusses nitric-oxide signaling, endothelial protection, and EGR-1/NAB2 and FAK-paxillin/JAK-2 pathways as proposed explanations, not established clinical mechanisms.
Relevance and study scope
It gives useful biological context for why BPC-157 is discussed in gastrointestinal and tissue-healing research, while keeping the ingredient separate from TB-500 and full-length thymosin beta-4.
This is a narrative review that emphasizes positive preclinical findings and does not establish a finished-spray result, canine benefit, oral absorption, or long-term safety. Its summarized experiments are heterogeneous and mostly use small laboratory animals.
exact ingredient study
MODULATORY EFFECT OF GASTRIC PENTADECAPEPTIDE BPC 157 ON ANGIOGENESIS IN MUSCLE AND TENDON HEALING
Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. MODULATORY EFFECT OF GASTRIC PENTADECAPEPTIDE BPC 157 ON ANGIOGENESIS IN MUSCLE AND TENDON HEALING. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191-196.
Species and research route: Human endothelial-cell angiogenesis assay and male Wistar rats with muscle-crush, quadriceps-transection, or Achilles-tendon-transection injuries; BPC-157 10 micrograms/kg intraperitoneally in rats.
What researchers found: BPC-157 did not significantly increase tubule branching in the cell-culture assay at the tested concentrations. In the rat injury models, treated tissue showed an earlier or stronger pattern of VEGF, CD34, and FVIII immunostaining, which the authors interpreted as an in-vivo angiogenic or angiomodulatory response during healing.
Relevance and study scope
The negative cell result is important: the paper does not show a simple direct angiogenic effect. Its rat findings provide a specific example of the proposed vascular-healing mechanism for exact BPC-157, separate from evidence about TB-500.
The work used small rat groups, induced injuries, intraperitoneal dosing, and tissue markers rather than canine outcomes or food exposure. Marker changes cannot establish that a food-bowl spray reaches injured tissue or improves an individual dog's recovery.
mechanism review
Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Mechanisms of Action and Probable Toxicity
Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Mechanisms of Action and Probable Toxicity. Pharmaceuticals. 2025;18(2):185. doi:10.3390/ph18020185.
Species and research route: Critical review of predominantly rat and mouse studies using varied routes; it also discusses limited dog and other preclinical material.
What researchers found: The review summarizes proposed BPC-157 interactions with nitric-oxide, vascular, inflammatory, and repair pathways but stresses that the mechanism, metabolic enzymes, binding interactions, and adverse effects remain incompletely defined. It notes that most studies are small-animal experiments with limited routes and that completed clinical efficacy studies are absent.
Relevance and study scope
This newer review adds a needed counterweight to highly positive mechanistic summaries: it helps an owner distinguish a plausible research mechanism from demonstrated safety or efficacy for Recovery Ranger.
It is a secondary review, not a new canine efficacy study, and its conclusions cannot determine the behavior of a particular formulation in food. The authors specifically call for more systematic toxicity, pharmacokinetic, interaction, and mechanism work.
related molecule context
The actin binding site on thymosin beta4 promotes angiogenesis
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003;17(14):2103-2105. doi:10.1096/fj.03-0121fje. PMID:14500546.
Species and research route: Human umbilical-vein endothelial-cell migration and adhesion assays plus chick aortic-ring sprouting; natural full-length thymosin beta-4, proteolytic fragments, and synthetic peptides tested in vitro or ex vivo.
What researchers found: The paper identifies full-length thymosin beta-4 as a 43-amino-acid, approximately 5-kDa G-actin-sequestering peptide. A seven-amino-acid actin-binding motif reproduced angiogenic activity near 50 nM in endothelial-cell migration and chick aortic-ring assays, while peptides missing part of that motif were inactive; soluble actin inhibited adhesion and sprouting.
Relevance and study scope
It explains a concrete cellular mechanism often invoked for thymosin beta-4 tissue research and makes the molecule distinction explicit. These findings should not be reassigned to an incompletely specified TB-500 material or to BPC-157.
The experiments were cell-based or ex vivo and did not test dogs, oral or food delivery, a finished formula, or functional recovery. A fragment's activity in these assays does not establish that a commercial TB-500 preparation has the same sequence, exposure, or effect.
related molecule context
Progress on the Function and Application of Thymosin β4
Xing Y, et al. Progress on the Function and Application of Thymosin β4. Frontiers in Cell and Developmental Biology. 2021;9:767395. doi:10.3389/fcell.2021.767395.
Species and research route: Review spanning cell culture, rodent and other mammalian models, and selected human studies with topical, local, systemic, or experimental administration; not a TB-500 dog study.
What researchers found: The review describes full-length thymosin beta-4 as 43 amino acids and summarizes work in which thymosin beta-4 or its fragments affected endothelial-cell migration, capillary-like structures, VEGF-associated signaling, proliferation, and apoptosis-related measures. It also notes that different sequence regions have been assigned different activities.
Relevance and study scope
This is useful background for reading thymosin literature without treating every beta-4 fragment or derivative as TB-500. It supports discussing mechanism as broader molecule context, not as direct evidence for Recovery Ranger.
The review combines heterogeneous models, routes, sequences, and outcomes, so it cannot identify the sequence or predict exposure of the finished ingredient. It does not establish canine efficacy, food-route stability, dosing, or safety for TB-500 plus BPC-157.
delivery research
Oral delivery of protein and peptide drugs: from noninvasive to invasive delivery strategies
Chen G, et al. Oral delivery of protein and peptide drugs: from noninvasive to invasive delivery strategies. Theranostics. 2022;12(3):1419-1443. doi:10.7150/thno.66931.
Species and research route: General review of oral protein and peptide delivery research, including in-vitro, animal, and translational formulation studies; not specific to BPC-157, TB-500, dogs, or a food-bowl spray.
What researchers found: The review explains that oral peptides face salivary, gastric, and intestinal proteases, mucus and epithelial barriers, enzymatic metabolism, efflux, and post-absorptive clearance. It describes nanoparticles, lipid systems, hydrogels, absorption enhancers, and pH-sensitive enteric coatings as investigated approaches, while noting limited drug loading, aggregation, manufacturing difficulty, instability, possible cytotoxicity, and the need for more translation work.
Relevance and study scope
It gives an evidence-based reason not to infer oral or food-route absorption from injected BPC-157 or thymosin studies. It also helps an owner understand why a delivery claim requires direct stability, exposure, and formulation testing rather than a mechanism analogy.
This is broad delivery literature and does not test either Recovery Ranger ingredient or the finished spray. Improvements reported for other peptides, carriers, or enteric systems cannot be transferred to this product without direct experiments.
exact ingredient study
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740.
Species and research route: Obese ob/ob mice and lean C57BL/6J mice; AOD9604 was delivered for 14 days with mini-osmotic pumps. Separate BaF-BO3 cells expressing the human growth-hormone receptor were used for binding and proliferation assays.
What researchers found: In obese mice, AOD9604 reduced body-weight gain, increased fat oxidation, and increased plasma glycerol, an index of lipolysis. Unlike full-length human growth hormone, it did not cause hyperglycaemia or reduce insulin secretion in this experiment. AOD9604 did not compete for the human growth-hormone receptor and did not induce receptor-associated cell proliferation in the tested cell system.
Relevance and study scope
This is useful mechanistic context for separating AOD-9604 from full-length growth hormone: the reported metabolic readouts occurred without the tested classical receptor interaction or cell-proliferation response. It is also closer to the ingredient than studies of unrelated peptides, while still being preclinical.
The intervention was in mice using implanted pumps, not dogs, oral food exposure, or a metered spray. The cell assay used a human receptor system and cannot establish the receptor biology of canine tissues or identify the finished product's active route. Mouse weight and lipid findings do not establish a movement or joint outcome in dogs.
exact ingredient study
Detection and in vitro metabolism of AOD9604
Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Drug Testing and Analysis. 2015;7(1):31-38. doi:10.1002/dta.1715.
Species and research route: AOD9604 was incubated in serum and urine in vitro; the study also validated extraction and mass-spectrometry detection in human urine and quantified metabolites in serum.
What researchers found: The authors describe AOD9604 as the C-terminal human-growth-hormone fragment 177-191 with an added N-terminal tyrosine. They identified six potential metabolites after serum and urine incubation; one serum metabolite, CRSVEGSCG, was more stable than the parent peptide or the other detected metabolites. The work validated a urine method with a reported 50 pg/mL detection limit.
Relevance and study scope
This paper helps explain that measuring the parent peptide is not the same as demonstrating intact exposure: AOD-9604 underwent detectable breakdown in the tested biological matrices. It adds analytical and metabolism context when considering any oral or food-contact route.
This was an analytical validation and in-vitro metabolism study, not a dosing study, absorption study, canine study, or efficacy trial. It does not show how much intact AOD-9604 would remain after contact with dog food, nor does it establish safety, stability, or an owner-facing outcome for the spray.
delivery research
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health
Moré MI, Kenley D. Journal of Endocrinology and Metabolism. 2014;4(3):64-77. doi:10.14740/jem213w.
Species and research route: Nonclinical program including oral gavage in rats for 6 months and cynomolgus monkeys for 9 months, intravenous dosing in rats, and oral or intravenous AOD9604 in pigs for pharmacokinetic sampling; in-vitro genotoxicity assays used bacterial and CHO-cell systems.
What researchers found: The report found no mutagenic signal in its Ames, chromosome-aberration, or bone-marrow micronucleus assays and reported no major treatment-related toxicological concern in the described chronic oral rat and monkey studies. In the pig pharmacokinetic experiment, orally administered AOD9604 was detected and showed rapid degradation; the report also described whole-body distribution of radiolabeled material in rats after oral or intravenous dosing.
Relevance and study scope
This is the most directly useful additional source for understanding that oral exposure and degradation were investigated in laboratory species, while also showing that route-specific pharmacokinetics matter. It provides broader context for interpreting an oral or food-applied concept without converting animal toxicology into a dog-product conclusion.
The paper is a sponsor-linked nonclinical report and its oral studies used gavage, not a dog-food spray. Detection of material after oral dosing does not establish intact-peptide absorption, effective exposure, palatability, product stability, or efficacy. The described species, doses, formulations, and study conditions do not validate the finished spray in dogs.
exact ingredient study
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Stier H, Vos E, Kenley D. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. doi:10.4021/jem157w.
Species and research route: Six randomized, double-blind, placebo-controlled human trials; the program included oral and intravenous clinical studies, with blood testing for IGF-1, glucose-tolerance measures, and anti-AOD9604 antibodies.
What researchers found: The authors' pooled clinical-trial safety summary reported no change in serum IGF-1, no adverse effect on carbohydrate metabolism in the reported oral-glucose-tolerance testing, and no anti-AOD9604 antibodies in the patients selected for antibody testing. No study reported a withdrawal or serious adverse event attributed to intake in the summarized trials.
Relevance and study scope
This source adds human evidence about selected biomarkers and tolerability, and it supports keeping AOD-9604 distinct from full-length growth hormone when discussing IGF-1 and glucose-related endpoints. It also supplies an important negative result: the clinical safety synthesis did not establish a movement benefit.
This is a summary of human trials, not a canine study and not an evaluation of a food-bowl spray. The abstract does not provide a canine dose, formulation, route, long-term dog safety dataset, or movement endpoint. Absence of a reported signal in these selected trials cannot guarantee safety for an individual dog or for this finished product.
mechanism review
Obesity Pharmacotherapy: Current Perspectives and Future Directions
Misra M. Current Cardiology Reviews. 2013;9(1):33-54. doi:10.2174/157340313805076322.
Species and research route: Narrative review of obesity-pharmacotherapy research across human clinical studies and animal or cellular models; the AOD-9604 discussion summarizes oral human development and earlier preclinical work rather than presenting a new experiment.
What researchers found: The review describes AOD-9604 as an orally active analogue of the lipolytic region of human growth hormone and reports mixed human development: an earlier 12-week study was summarized as showing greater average weight loss than placebo, whereas a later 24-week trial in 536 people did not find significant weight loss. The review therefore presents AOD-9604 as an investigational candidate with inconsistent clinical efficacy rather than an established obesity treatment.
Relevance and study scope
This broader review is useful for placing the animal metabolic findings beside the human evidence and for preserving the negative or mixed clinical result. It helps prevent a mouse fat-metabolism result from being presented as a predictable outcome for a dog or as evidence for movement support.
It is a 2013 narrative review and does not test AOD-9604, dogs, joint function, food delivery, or the finished spray. Its clinical-trial summaries are secondary reporting, and the review's obesity focus does not establish any canine movement, mobility, safety, or disease-prevention effect.
mechanism review
Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells
Wang XY, Qu M, Duan R, et al. Neuroscience Bulletin. 2019;35(1):167-170. doi:10.1007/s12264-018-0269-8. PMID:30116973.
Species and research route: Ex vivo human jejunum, ileum, and colon strips; rat stomach, jejunum, ileum, and colon strips; cultured rat ileal and colonic enteric neurons and enteric glial cells; direct bath or culture-medium exposure to BPC-157, not a live-animal treatment route.
What researchers found: In isolated rat and human intestinal preparations, 40 micromol/L BPC-157 reduced the amplitude of spontaneous muscle contractions. It also lowered measured enteric 5-HT in rat ileal and colonic samples, while the human 5-HT result was inconsistent and did not show the same reduction in samples from patients with colonic cancer. In rat cell cultures, 100 micromol/L BPC-157 increased four-week survival of ileal enteric neurons from 19.23% in controls to 31.69% and increased enteric-glial proliferation from 147.98% to 159.95% of the day-three cell count.
Relevance and study scope
This is useful broader mechanism reading because it connects BPC-157 with enteric serotonin measurements, intestinal motility, enteric neurons, and enteric glia rather than relying only on ulcer-area endpoints. The mixed human tissue findings also show why a laboratory mechanism should not be treated as a uniform digestive effect.
The study used isolated tissues and cultures, not dogs or a food-applied product. Concentrations were direct experimental exposures, and the authors stated that the detailed signaling pathway in enteric neurons and enterocytes still required further investigation; the results do not establish oral absorption, finished-product performance, safety, or a clinical digestive outcome.
exact ingredient study
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat
Vuksic T, Zoricic I, Brcic L, et al. Surgery Today. 2007;37(9):768-777. doi:10.1007/s00595-006-3498-9. PMID:17713731.
Species and research route: Rats with surgically created ileoileal anastomoses; BPC-157 10 micrograms/kg, 10 nanograms/kg, or 10 picograms/kg administered intraperitoneally once daily, beginning after surgery and ending 24 hours before assessment.
What researchers found: At the two higher tested doses, the investigators reported improvement across macroscopic, histologic, and biomechanical measures of anastomotic healing. Edema was lower from day one, granulocyte numbers decreased, and from days four or five the study reported less necrosis with more granulation tissue, reticulin, collagen formation, and epithelialization; adhesion formation remained slight and temporary mild obstruction was observed.
Relevance and study scope
This adds a distinct intestinal-surgery model to the existing gastric-ulcer evidence and shows the kinds of tissue-integrity endpoints researchers have used for BPC-157. It may help explain why intestinal repair is a recurring research topic without converting a postoperative rat result into an everyday-digestion claim.
This was a rat surgical-injury experiment with intraperitoneal dosing, not a canine study, routine feeding study, or food-bowl spray. It measured healing of a deliberately created anastomosis rather than normal gastrointestinal function, and it does not establish absorption, dosing, safety, stability, or efficacy for Belly Balance.
exact ingredient study
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability
Klicek R, Kolenc D, Suran J, et al. Journal of Physiology and Pharmacology. 2013;64(5):597-612. PMID:24304574.
Species and research route: Wistar rats with intrarectal cysteamine colitis or colon-colon anastomosis; BPC-157 given intraperitoneally at 10 micrograms/kg or 10 nanograms/kg once daily, or orally in drinking water at 0.16 micrograms/mL or 0.16 nanograms/mL; the paper also used an intragastric route in a separate cuprizone model.
What researchers found: In the reported experiments, untreated controls did not heal the cysteamine colitis or colon-colon anastomosis, whereas BPC-157 treatment was described as producing efficient healing in both models. The authors tested both intraperitoneal dosing and drinking-water exposure, and assessed colon injury and anastomosis endpoints alongside histologic and functional measures; the same paper also reported less cuprizone-related neural damage and better motor measures, which are separate from the GI experiments.
Relevance and study scope
This is one of the more directly relevant broader readings for gastrointestinal research because it includes chemically induced colitis, a colon surgical model, and an oral drinking-water exposure rather than only injection. It helps distinguish a controlled injury model from a claim about a healthy dog’s ordinary digestion.
All intervention findings were in rats, with induced disease or surgery and laboratory administration. The drinking-water route is not equivalent to a metered spray applied to dog food, and the study did not test dogs, the finished product, palatability, stability in food, or clinical digestive outcomes.
mechanism review
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats—A Review
Bajramagic S, Sever M, Rasic F, et al. Pharmaceuticals. 2024;17(8):1081. doi:10.3390/ph17081081. PMID:39204186.
Species and research route: Review of preclinical rat studies involving intestinal and other gastrointestinal anastomoses, fistulas, short-bowel and colitis models; routes across the reviewed studies include intraperitoneal, oral/drinking-water, intragastric, and local administration.
What researchers found: The review organizes reported BPC-157 findings across esophagogastric, colocolonic, jejunoileal, and ileoileal anastomoses, as well as several fistula and intestinal-adaptation models. It presents recurring discussions of epithelial and endothelial integrity, nitric-oxide and prostaglandin systems, and collateral vascular responses as possible explanatory themes, while the underlying evidence remains predominantly rat preclinical work.
Relevance and study scope
This provides a broader map of the gastrointestinal literature and clarifies that the research question is often surgical tissue repair or induced injury, not routine digestive wellness. It is useful for understanding how proposed mechanisms are assembled across multiple models and routes.
This is a narrative review rather than a new controlled trial, and its conclusions depend largely on a preclinical literature concentrated in rats and on studies from related research programs. It does not establish canine efficacy, oral bioavailability from food, finished-spray safety or stability, a dose, or prevention or treatment of disease in an individual dog.
mechanism review
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987.
Species and research route: Review of human-cell, animal, and tissue-repair literature; routes and models varied and were not standardized to oral or food delivery.
What researchers found: The review describes GHK/GHK-Cu research involving collagen, elastin, glycosaminoglycan, fibroblast, angiogenesis, inflammatory, and gene-expression measurements. It emphasizes that the literature spans multiple biological systems and proposed pathways rather than one demonstrated skin or coat outcome.
Relevance and study scope
It explains why GHK-Cu is studied in connective-tissue remodeling and places collagen-related findings alongside broader cellular observations. It also helps separate mechanistic and preclinical evidence from evidence about a finished canine spray.
This is a narrative review, not a new controlled canine study. It includes heterogeneous studies, some involving GHK rather than the copper complex, and does not establish oral absorption, product stability, safety, or a skin or coat benefit in dogs.
delivery research
A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Archives of Internal Medicine Research. 2026;9(3):269-293. doi:10.26502/aimr.0255.
Species and research route: Systematic review of in vitro, ex vivo, rodent, non-rodent, and human studies, with emphasis on topical and microneedle delivery; no canine food-bowl route was tested.
What researchers found: The review retained 64 records and reports that the human literature remains small and heterogeneous. It identifies a major gap: no adequately powered published human randomized trial had evaluated GHK-Cu delivered by a microneedle platform, while study concentrations, topical formulations, outcomes, and methods varied substantially; it also notes that most human studies were small and often incompletely reported.
Relevance and study scope
This is useful for understanding delivery as a separate scientific question from ingredient mechanism. It supports cautious interpretation of topical and enhanced-delivery results and makes clear that those findings cannot establish behavior in a meal-applied spray.
The review is recent and its conclusions depend on the quality and reporting of the included studies; it is not a canine efficacy or safety trial. Microneedle, cream, ex vivo skin, and cell studies do not demonstrate that GHK-Cu survives food contact, reaches canine skin, or produces a finished-product outcome.
exact ingredient study
The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures
Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences. 2000;67(18):2257-2265. doi:10.1016/S0024-3205(00)00803-1. PMID:11045606.
Species and research route: Cultured dermal fibroblasts; direct in-vitro exposure to GHK-Cu, copper ions, or GHK without a live-animal route.
What researchers found: GHK-Cu increased matrix metalloproteinase-2 in fibroblast-conditioned media and increased MMP-2 messenger RNA. It also increased secretion of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2; copper ions reproduced the effect, whereas GHK alone did not under the study conditions.
Relevance and study scope
The findings add a specific extracellular-matrix remodeling mechanism rather than treating collagen synthesis as the only relevant endpoint. The paired MMP and inhibitor findings help explain why remodeling biology is more complex than simply increasing one structural protein.
This was a cell-culture experiment with no dog, no intact skin, no oral exposure, and no coat endpoint. Changes in MMP and TIMP measurements do not show improved healing, absorption, safety, or efficacy of a food-bowl spray.
exact ingredient study
Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
Siméon A, Monier F, Emonard H, Gillery P, Birembaut P, Hornebeck W, Maquart FX. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Journal of Investigative Dermatology. 1999;112(6):957-964. doi:10.1046/j.1523-1747.1999.00606.x. PMID:10383745.
Species and research route: Male Sprague-Dawley rats with subcutaneous wound chambers; serial local injections of 2 mg GHK-Cu or saline.
What researchers found: In this wound-chamber model, GHK-Cu did not alter interstitial collagenase activity. It increased pro-MMP-2 and activated MMP-2 during later healing stages, while the study described stage-specific expression of MMP-2 and MMP-9 across the healing process.
Relevance and study scope
The paper is useful because it shows a time-dependent remodeling result and includes a negative finding, rather than implying that every wound enzyme endpoint moved in the same direction. It gives context for how GHK-Cu may be investigated in tissue repair without converting rat injection data into canine coat claims.
This was a rat wound model using local injections, not a dog study and not oral or food delivery. The enzyme changes are surrogate mechanistic measurements; they do not establish a visible benefit, general skin improvement, dose equivalence, or finished-spray performance.
exact ingredient study
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006;8(4):252-259. doi:10.1001/archfaci.8.4.252. PMID:16847171.
Species and research route: Randomized human topical study; 13 patients completing post-CO2-laser resurfacing regimens with or without a GHK-Cu skin-care product.
What researchers found: Blinded evaluators and computer analysis found no statistically significant difference in the speed or resolution of erythema. Objective assessments also found no significant between-group improvement in wrinkles or overall skin quality, although questionnaire-based satisfaction favored the GHK-Cu group.
Relevance and study scope
This small randomized study adds an important mixed result: subjective satisfaction differed, while the main objective skin measures did not. It helps prevent broad claims that topical GHK-Cu consistently improves visible skin outcomes and reinforces that human topical evidence is not canine oral evidence.
Only 13 patients completed the study, and the intervention followed laser resurfacing in human skin rather than routine use in dogs. It did not test ingestion, food contact, coat or hair endpoints, long-term safety, or the finished spray.
exact ingredient study
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702. PMID:17018654.
Species and research route: Healthy men aged 20–40 years; single subcutaneous CJC-1295 injection at 60 or 90 micrograms/kg; overnight serial blood sampling before and one week after dosing.
What researchers found: CJC-1295 increased overall GH and IGF-1 secretion while preserving the pulsatile pattern of GH release. The reported change was driven mainly by a 7.5-fold increase in trough GH; mean GH rose 46% and IGF-1 rose 45%, with no significant difference between the two tested doses.
Relevance and study scope
This adds detail to the existing human CJC-1295 pharmacology evidence by showing that a long-acting GHRH analogue did not simply replace pulses with a flat signal under these conditions. It helps explain why GH and IGF-1 measurements are mechanistic endpoints rather than proof of improved vitality, movement, or lifespan in dogs.
The study involved a small, short human clinical experiment using subcutaneous injection of CJC-1295 alone. It did not test dogs, Ipamorelin, the exact combination, food exposure, a spray, or owner-facing outcomes; its findings cannot establish canine efficacy or safety.
related molecule context
Structural basis for activation of the growth hormone-releasing hormone receptor
Zhou F, Zhang H, Cong Z, et al. Nat Commun. 2020;11(1):5205. doi:10.1038/s41467-020-18945-0. PMID:33060564.
Species and research route: Human GHRH receptor studied by cryo-electron microscopy with endogenous GHRH and stimulatory G protein; receptor mutagenesis and cAMP assays in HEK293T cells; no administered animal or human route.
What researchers found: The study resolved a 2.6-angstrom structure of human GHRH bound to GHRHR and stimulatory G protein. It showed that GHRH makes an extensive interaction network across extracellular loops, transmembrane helices, and the receptor extracellular domain, and that selected disease-associated receptor mutations impair signaling in cellular assays.
Relevance and study scope
This provides receptor-level context for CJC-1295 as a GHRH-related signaling agent: receptor activation depends on defined molecular contacts and downstream G-protein signaling, not on a generic claim that any peptide raises growth hormone. It also illustrates why results from human receptor structure and cell assays should not be treated as a direct test of Prime Pup in dogs.
The paper studied endogenous human GHRH and human receptor constructs, not CJC-1295, Ipamorelin, canine receptors, a food route, or a finished product. Structural and cell-signaling findings explain mechanism but do not establish absorption, clinical benefit, or safety in dogs.
delivery research
Approaches for Enhancing Oral Bioavailability of Peptides and Proteins
Renukuntla J, Vadlapudi AD, Patel A, Boddu SHS, Mitra AK. Int J Pharm. 2013;447(1-2):75-93. doi:10.1016/j.ijpharm.2013.02.030. PMID:23428883.
Species and research route: Review of oral peptide and protein delivery barriers and enhancement technologies, including GI, cell, membrane, and preclinical transport studies; no single species or administered route applies to the review as a whole.
What researchers found: The review states that oral peptide and protein bioavailability is commonly very low because of gastrointestinal enzymatic degradation and poor epithelial permeability, and it discusses protective carriers, nanoparticles, absorption enhancers, enzyme inhibitors, and targeting strategies. It emphasizes that a viable system must preserve molecular integrity, release material at an absorption site, and retain it long enough for uptake; many approaches had limited success at the time of publication.
Relevance and study scope
This complementary review helps an owner understand why injection pharmacokinetics cannot be transferred to a meal-applied spray. It also makes clear that an oral delivery claim requires evidence about intact peptide stability and transport, not merely evidence that the unmodified ingredient has activity after injection.
The review is not specific to CJC-1295, Ipamorelin, dogs, or this product, and its literature predates some newer oral peptide technologies. Its general barriers and cautions do not quantify Prime Pup exposure or predict an individual dog's response.
exact ingredient study
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. J Exp Pharmacol. 2012;4:149-155. doi:10.2147/JEP.S35396. PMID:27186127.
Species and research route: Adult male Sprague-Dawley rats with surgically induced postoperative ileus; intravenous Ipamorelin at 0.014 or 0.14 micromoles/kg; ex vivo rat gastric-fundus contractility assays.
What researchers found: In rats whose abdominal surgery and intestinal manipulation delayed gastric emptying, intravenous Ipamorelin reduced the radiolabeled meal remaining in the stomach and improved small-intestinal transit; the higher tested dose produced the stronger transit response. In isolated gastric tissue from the same model, Ipamorelin reversed impaired acetylcholine- and electrically stimulated contractile responses, supporting a ghrelin-receptor and enteric-neural mechanism under the experimental conditions.
Relevance and study scope
This paper adds a non-GH endpoint for Ipamorelin and shows that ghrelin-receptor biology can affect gastrointestinal motility in a specific injury and surgery model. It is useful mechanistic context, but it should not be read as evidence that Prime Pup changes digestion or motility in healthy mature dogs.
The experiment used small groups of rats, intravenous dosing, a surgically induced postoperative-ileus model, and short-term measurements. It did not test dogs, CJC-1295, the exact combination, oral or food delivery, a finished spray, chronic exposure, or routine digestive outcomes.
exact ingredient study
The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress
Kim KH, Son JM, Benayoun BA, Lee C. Cell Metabolism. 2018;28(3):516-524. doi:10.1016/j.cmet.2018.06.008.
Species and research route: In vitro human-cell and molecular experiments; exogenous fluorescent MOTS-c exposure, genetic expression and localization assays; no animal dosing route.
What researchers found: The study found that endogenous MOTS-c was mainly extra-nuclear with some mitochondrial association at baseline, while fluorescent MOTS-c could show mitochondrial and nuclear localization within 30 minutes of treatment. Mutation experiments implicated the hydrophobic 8YIFY11 region in nuclear entry, whereas changing the basic 13RKLR16 sequence did not block entry; nuclear-loss mutants still reduced cellular oxygen consumption, suggesting that not all effects require nuclear localization.
Relevance and study scope
This is direct native-MOTS-c mechanistic evidence that makes the mitochondrial-to-nuclear signaling idea more concrete and shows that sequence-dependent protein interactions may matter. It helps explain why a change in a cellular endpoint cannot automatically be read as a whole-animal vitality or cognition result.
The work used cultured cells, fluorescent or genetically expressed constructs, and molecular endpoints rather than dogs, oral administration, food exposure, or a finished spray. It does not establish extracellular stability, gastrointestinal absorption, product behavior, or an owner-observable outcome.
exact ingredient study
MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway
Yang B, Yu Q, Chang B, et al. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2021;1867(6):166126. doi:10.1016/j.bbadis.2021.166126.
Species and research route: C2C12 mouse myotubes in vitro and male C57BL mice with high-fat-diet-induced obesity; recombinant MOTS-c supplementation and treadmill-training intervention, with the abstract not specifying a canine or oral route.
What researchers found: In C2C12 myotubes, AMPK inhibition reduced PGC-1α and MOTS-c expression, PGC-1α knockdown reduced MOTS-c expression, and PGC-1α overexpression or recombinant MOTS-c increased MOTS-c expression. In high-fat-diet mice, treadmill training increased muscle MOTS-c, PGC-1α, GLUT4, and phosphorylation of AMPK and ACC; the authors interpreted the findings as evidence of an AMPK/PGC-1α relationship and possible interaction between exercise and MOTS-c.
Relevance and study scope
This paper adds depth to the metabolic-signaling pathway by connecting native MOTS-c measurements with AMPK, PGC-1α, GLUT4, and exercise in a mouse model. It is useful for understanding a proposed cellular-energy mechanism, not for treating exercise-associated measurements as proof of a finished product effect.
The study used mouse cells and mice, not dogs, and its interventions were recombinant peptide supplementation or treadmill training rather than a food-bowl spray. It measured signaling, insulin resistance, and glucose-metabolism endpoints; it did not test cognition, daily vitality, oral absorption, finished-product stability, or long-term safety.
exact ingredient study
The Mitochondrial-Derived Peptide (MOTS-c) Interacted with Nrf2 to Defend the Antioxidant System to Protect Dopaminergic Neurons Against Rotenone Exposure
Xiao J, Zhang Q, Shan Y, et al. Molecular Neurobiology. 2023;60(10):5915-5930. doi:10.1007/s12035-023-03443-3.
Species and research route: PC12 rat-derived cells exposed to rotenone and rats exposed to rotenone; exogenous MOTS-c pretreatment, with cellular localization and antioxidant-pathway measurements; the PubMed abstract does not specify the animal administration route.
What researchers found: In rotenone-exposed PC12 cells, more MOTS-c moved from mitochondria toward the nucleus, where the authors reported direct interaction with Nrf2 and regulation of HO-1 and NQO1. In cell and rat experiments, MOTS-c pretreatment reduced measured mitochondrial dysfunction and oxidative stress, preserved selected tyrosine-hydroxylase, PSD95, and synaptophysin signals, and partly normalized Nrf2, HO-1, NQO1, and Keap1 changes in striatum.
Relevance and study scope
This study gives a specific example of the proposed mitochondrial-to-nuclear mechanism and links native MOTS-c to an antioxidant-response pathway in a neurotoxicology model. It can help an owner understand why mechanistic papers may mention neuronal or oxidative-stress biology without establishing a cognitive benefit in dogs.
The experiments used rat-derived cells and a rotenone injury model in rats, not healthy dogs or a finished spray. Pretreatment in a toxin model is not evidence of prevention, treatment, cognition improvement, or routine vitality; the paper also does not establish oral absorption, food compatibility, stability, or safety for this product.
mechanism review
MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases
Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. International Journal of Molecular Sciences. 2022;23(19):11991. doi:10.3390/ijms231911991.
Species and research route: Review of human observational work, cell studies, and animal studies using varied experimental exposures; not a new dosing study and not a canine food-route study.
What researchers found: This review describes MOTS-c as a 16-amino-acid peptide encoded by the mitochondrial 12S rRNA region and summarizes reports that metabolic stress can accompany nuclear translocation, AMPK-related signaling, AICAR accumulation, and interactions with stress-response transcription factors including Nrf2/ARE. It also presents age-related and disease-related findings across studies while noting that the detailed entry and action mechanisms remain under investigation.
Relevance and study scope
The review is useful for connecting isolated findings about mitochondrial localization, AMPK, nuclear regulation, aging, and metabolism into one map of the research field. Its broad scope makes the species, route, endpoint, and evidence-quality differences visible rather than allowing them to be collapsed into a single dog claim.
This is a narrative review, not a canine efficacy or pharmacokinetic study. It discusses therapeutic potential but does not demonstrate that native MOTS-c survives food exposure, is absorbed from a spray, reaches a target tissue in dogs, or changes cognition, energy, movement, aging, or disease outcomes in an individual animal.
mechanism review
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Zheng Y, et al. Frontiers in Endocrinology. 2023;14:1120533. doi:10.3389/fendo.2023.1120533.
Species and research route: Review of cell, rodent, and human observational or experimental literature with varied routes; no new intervention and no canine food-route study.
What researchers found: The review summarizes MOTS-c as a 16-amino-acid mitochondrial-derived peptide and discusses reported links with skeletal-muscle metabolism, insulin sensitivity, exercise, and age-related research. It specifically notes uncertainty about how MOTS-c enters cells without degradation while retaining activity, and it identifies delivery and biosafety as unresolved development problems.
Relevance and study scope
This review is especially helpful for interpreting the gap between a plausible mechanism and a usable intervention: the literature includes promising preclinical signals but still has open questions about cellular uptake, delivery, and translation. It therefore supports a more precise reading of native-MOTS-c papers without treating engineered delivery concepts or rodent findings as evidence for this spray.
The article is a review rather than a dog study and includes heterogeneous evidence with different species, routes, and endpoints. It does not establish finished-spray absorption, stability, safety, dosing, or efficacy, and it cannot turn mouse or cell findings into canine cognition or daily-vitality evidence.
exact ingredient study
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
Falutz J, Allas S, Kotler D, et al. AIDS. 2005;19(12):1279-1287. doi:10.1097/01.aids.0000180099.35146.30. PMID:16052083.
Species and research route: Humans: 61 HIV-infected adults with increased waist circumference and waist-to-hip ratio; randomized, double-blind, placebo-controlled trial; TH9507 (tesamorelin) 1 or 2 mg subcutaneously once daily for 12 weeks.
What researchers found: Tesamorelin produced dose-related increases in IGF-1 of 48% at 1 mg and 65% at 2 mg versus placebo. At 2 mg, trunk fat decreased 9.2% versus a 0.8% increase with placebo, and visceral fat decreased 15.7% within the group, but the visceral-fat comparison versus placebo was not statistically significant. Subcutaneous fat was preserved, lean body mass and the visceral-to-subcutaneous-fat ratio improved, and the 2 mg group had lower triglycerides and a lower cholesterol-to-HDL ratio without a reported glucose increase over 12 weeks.
Relevance and study scope
This is an early controlled human study of the same active ingredient and shows both the endocrine signal and the distinction between a within-group change and a statistically significant placebo comparison. It helps explain why tesamorelin research focuses on visceral rather than general fat measures.
The study used daily subcutaneous injection in a selected HIV-associated abdominal-fat population for only 12 weeks. It did not test dogs, oral or food exposure, a spray, long-term clinical outcomes, or Heart Hero; the authors called for larger and longer studies, and the visceral-fat result was not significant versus placebo.
exact ingredient study
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Falutz J, Potvin D, Mamputu JC, et al. J Acquir Immune Defic Syndr. 2010;53(3):311-322. doi:10.1097/QAI.0b013e3181cbdaff. PMID:20101189.
Species and research route: Humans: 404 HIV-infected adults with antiretroviral-associated abdominal fat accumulation; randomized placebo-controlled trial followed by blinded rerandomization; tesamorelin 2 mg subcutaneously daily for 6 or 12 months.
What researchers found: After six months, visceral adipose tissue decreased 10.9% (21 cm²) with tesamorelin versus 0.6% (1 cm²) with placebo, while trunk fat, waist circumference, and waist-to-hip ratio improved without a change in limb or abdominal subcutaneous fat. IGF-1 increased, and glucose parameters did not change in the reported comparison. Among participants continuing tesamorelin for 12 months, visceral fat reduction was about 18%; participants who switched to placebo rapidly lost the earlier visceral-fat improvement.
Relevance and study scope
This longer controlled study clarifies the duration and reversibility of the best-known tesamorelin body-composition findings. The switch-to-placebo result is particularly useful for understanding that an injected study effect was not shown to persist independently of continued treatment.
Participants were adults with HIV-associated abdominal fat accumulation, not dogs or generally healthy aging animals. The route was subcutaneous injection, not ingestion or application to food, and the endpoints were body-composition, biomarker, and patient-reported measures rather than canine cardiovascular outcomes or finished-spray performance.
exact ingredient study
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Stanley TL, Feldpausch MN, Oh J, et al. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334. PMID:25038357.
Species and research route: Humans: 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation; double-blind randomized placebo-controlled trial; tesamorelin 2 mg subcutaneously daily for 6 months.
What researchers found: Among 48 participants who received study drug, tesamorelin reduced visceral adipose tissue by a mean 34 cm² versus an 8 cm² increase with placebo, for a treatment effect of -42 cm². Liver-fat lipid-to-water percentage also fell by a median 2.0% versus a 0.9% increase with placebo. Fasting glucose rose at two weeks, although six-month fasting and two-hour glucose differences were not statistically significant across time points. The authors described the trial as preliminary and said the clinical importance and long-term consequences required further study.
Relevance and study scope
This adds a directly measured liver-fat endpoint and documents an early glucose signal alongside the six-month results. It supports careful discussion of tesamorelin biology without turning a selected human surrogate-endpoint trial into a claim about heart health or canine disease prevention.
This was a small, preliminary human study in an HIV-associated fat-accumulation population using daily subcutaneous injection. It did not test dogs, oral or food-associated exposure, a metered spray, or cardiovascular events; the liver-fat and visceral-fat findings do not establish clinical benefit for Heart Hero.
exact ingredient study
Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin
Stanley TL, Falutz J, Marsolais C, et al. Clinical Infectious Diseases. 2012;54(11):1642-1651. doi:10.1093/cid/cis251. PMID:22495074. PMCID:PMC3348954.
Species and research route: Humans: pooled phase III randomized, double-blind studies of HIV-infected adults with abdominal fat accumulation; tesamorelin 2 mg subcutaneously each morning for 26 weeks, with a continued-treatment or switch-to-placebo extension to 52 weeks; responder analysis of 402 tesamorelin-treated participants at 26 weeks and 152 at 52 weeks with paired visceral-fat data.
What researchers found: The prespecified responder threshold was at least an 8% reduction in visceral adipose tissue. At 26 weeks, responders had larger reductions in triglycerides and smaller increases in fasting glucose, insulin, HbA1c, and HOMA-IR than nonresponders; adiponectin increased in responders. At 52 weeks, responders again had lower triglycerides and better glucose-related measures than nonresponders. The paper reports associations between visceral-fat change and metabolic measures; it does not prove that visceral-fat reduction alone caused each metabolic difference.
Relevance and study scope
This paper deepens interpretation of the human evidence by separating participants who did and did not meet a visceral-fat response threshold rather than treating every treated participant as equivalent. It also makes clear that metabolic findings were tied to an analysis of responders and nonresponders, not to a demonstrated dog or cardiovascular outcome.
This was a post hoc analysis of selected participants from two human HIV trials, not a new randomized comparison of responders. It used injected tesamorelin and did not test dogs, oral or food delivery, a spray, or Heart Hero; the associations cannot establish causation or predict an individual animal's response.
delivery research
Oral delivery of peptide drugs: barriers and developments
Hamman JH, Enslin GM, Kotzé AF. BioDrugs. 2005;19(3):165-177. doi:10.2165/00063030-200519030-00003. PMID:15984901.
Species and research route: Review of oral peptide and protein delivery research across human and animal literature; focuses on gastrointestinal administration, intestinal degradation, mucosal penetration, absorption enhancers, and adapted delivery systems rather than a tesamorelin trial.
What researchers found: The review explains that most peptide drugs remain parenteral because gastrointestinal absorption of intact peptides is inadequate. It identifies presystemic enzymatic degradation and poor intestinal-mucosa penetration as major barriers, and describes approaches including altered peptide physicochemical properties, functional excipients, and specialized delivery systems. It also notes unresolved concerns such as excipient toxicity, person-to-person absorption variability, and manufacturing cost.
Relevance and study scope
Tesamorelin's existing canine evidence uses pulmonary or injected administration, so this review supplies the missing route biology needed to avoid assuming that exposure from those routes transfers to a food-associated route. It helps an owner understand why a food-bowl format would require its own stability, release, absorption, and exposure evidence.
This is a broad delivery review, not a tesamorelin study and not evidence that any particular spray, food matrix, excipient, or formulation overcomes the stated barriers. It does not establish Heart Hero stability, absorption, dosing, safety, or efficacy in dogs.
delivery research
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives
Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharmaceutica Sinica B. 2021;11(8):2416-2448. doi:10.1016/j.apsb.2021.04.001.
Species and research route: Review of oral protein and peptide delivery research across laboratory and pharmaceutical systems; no Cardiogen-specific experiment and no canine finished-product test.
What researchers found: The review describes two central barriers to oral peptide exposure: rapid degradation in changing gastrointestinal pH and enzyme environments, and poor passage through mucus and intestinal epithelium. It surveys approaches such as enteric protection, enzyme inhibitors, permeation enhancers, chemical modification, and nanocarriers; these are specialized delivery strategies, not properties that can be inferred from a simple food-applied spray.
Relevance and study scope
This gives useful mechanistic context for why an injected or ex-vivo result involving a peptide called Cardiogen cannot establish intact oral exposure. It also supports keeping any AEDR transporter or delivery discussion conditional: the review concerns peptide-delivery technologies generally and does not identify the Daily Defense material as AEDR.
This is a broad review rather than a Cardiogen study. Its examples include other peptides, engineered formulations, and non-canine systems, so it does not establish Cardiogen stability, absorption, safety, or efficacy in dogs or in the finished formula.
delivery research
Impact of gastrointestinal differences in veterinary species on the oral drug solubility, in vivo dissolution, and formulation of veterinary therapeutics
Martinez MN, Papich MG, Fahmy R. Impact of gastrointestinal differences in veterinary species on the oral drug solubility, in vivo dissolution, and formulation of veterinary therapeutics. ADMET & DMPK. 2022;10(1):1-25. doi:10.5599/admet.1140.
Species and research route: Veterinary pharmacokinetic and formulation review covering dogs, cats, and other veterinary species; oral drug administration and gastrointestinal dissolution/solubility considerations.
What researchers found: The review explains that canine body size, intestinal dimensions, transit, gastric and intestinal pH, bile composition, fed state, and other gastrointestinal variables can affect dissolution and oral performance. It notes that canine gastric and intestinal conditions differ from human conditions and that information about fed canine gastrointestinal fluids is limited, making formulation and exposure predictions uncertain.
Relevance and study scope
Because Daily Defense is described as food-associated oral use, this paper helps explain why human or generic peptide-delivery assumptions do not substitute for dog-specific testing. It also makes clear that a dog route question involves the food matrix and canine physiology, not just whether a short sequence has a plausible transporter interaction in a model.
This review is not about Cardiogen, AEDR, ultrashort bioregulator peptides, or the finished spray. It discusses oral veterinary therapeutics broadly and therefore cannot demonstrate gastrointestinal stability, absorption, or a biological outcome for this ingredient.
mechanism review
Therapeutic peptides: current applications and future directions
Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7:48. doi:10.1038/s41392-022-00904-4.
Species and research route: Review of therapeutic-peptide discovery, modification, pharmacology, and delivery across human and experimental systems; no Cardiogen-specific or canine oral trial.
What researchers found: The review states that peptides are generally vulnerable to hydrolysis by digestive enzymes, which is why many peptide medicines are administered by injection. It describes how chemical modification, lipid conjugation, enzyme protection, and permeation enhancers can change stability or delivery, while emphasizing that these strategies concern particular engineered molecules and formulations; for example, oral semaglutide depends on a specific modified peptide and SNAC co-formulation.
Relevance and study scope
This helps distinguish a general peptide mechanism or sequence discussion from evidence about a product’s route and analyte. It is particularly relevant to Cardiogen because the exact formula sequence is unconfirmed: evidence for a different engineered peptide, a different conjugate, or a different delivery system cannot be assigned to Cardiogen or treated as proof of finished-spray performance.
This is a broad review of therapeutic peptides, not a Cardiogen or AEDR primary study. Its examples largely involve human medicines and engineered molecules, so it does not establish native Cardiogen identity, dog pharmacokinetics, gastrointestinal stability, safety, dosing, or efficacy.